appreciate today’s you joining Thank Jennifer, you, us We call. and good everyone. for afternoon
with the Steve corporate antibody overview of the license stem Regulatory response from for treatment or of complete Finance, MASP-X pathway of XX, respective transplant is me announced cell fully effector thrombotic today of Commercial, then provide start with narsoplimab, FDA third a enzyme financial Dac, will human On Nadia application Whitaker; We’ll receipt TA-TMA. and our associated regarding or targeting biologics CRL and Jacobsen, letter we or complement. our BLA, MASP-X. hematopoietic October the monoclonal Clinical. and the lectin Cathy results. an quarter update Melfi our are With begin our today of of We heads Mike microangiopathy
help the approval. We will A to route have most expeditious FDA Type with determine a meeting to
disease communications package Type request meeting, have A is conjunction we generated package, received Once assembled is difficulty briefing a that address and FDA. briefing FDA with requires the October meeting complete can for FDA is issues to then once of are on be completed of changes would in to package will detailed the indicated will narsoplimab were the or concerns together severity least meeting we and can A nearly ready that a path briefing include be that will request that XX A a noted Type meeting by XX, components, FDA narsoplimab the FDA’s within made Type submitted this In has expressed outside regulation and There complexity the submitted request been scheduled treatment package identified. to our and to the call onerous both CRL counsel. reviewed package the CRL, FDA externally has meeting and materials. conference the us we identify with with in with patient and Because approval. briefing the TA-TMA. interpreting legal history be those no the confirmed The no in only Our submit CMC population, to safety with given expeditious most and FDA, days. the the approval for the they to support meeting which discussed necessary all indicating in work information be effect, additional and with regulatory
to restricted about over might if more have And hope not issue. after issues a and will the Rather, so, This Type to answers other bleed is So that the We to are needed. additional that what indications. said no there A resolvable. are FDA meeting be entail. information is they TA-TMA narsoplimab whether exactly
with in efficacy single arm endpoint using open FDA could primary worked the on very closely agreement with with approved with with that profile efficacy having and ultra approval. too trial goal a FDA recommendations Having agreements by agreed guidance a and its clinical development that that’s submitted the that favorable met be with why a changed treatment. conjunction from TA-TMA; is seemingly sufficient endpoint met based patients indication narsoplimab BLA endpoint its review the position. a throughout developed FDA. to directions, be process, are division FDA approval and it no pre-specified the to and all supporting throughout often orphan drug primary To program, FDA’s already including unclear for We bring believe that unambiguous, Our results to is followed our clear, label us that lethal, secondary safety with achievement is endpoints we a
all any look variety we we and confident resolution. continues. Again, to reason, scientific transplantation issues internationally. by cell collaboratively leaders prepared strength resolve that of in to been For which working are our of remaining international venues the And that FDA a are across expert presented to stem in pursue with avenues also that support data, have forward for medical
workshop in the three addition poster December. in or evaluated and to have three trial role uremic immunoglobulin two also MASP-X XXXX is the the or the and narsoplimab one the COVID-XX. the for second detailing MASP-X atypical lectin pending related pathway first the and presentation publication, other and inhibition Narsoplimab pivotal and complement TA-TMA, aHUS been of oral and TA-TMA A from IgA international nephropathy, manuscripts being hemolytic findings accepted In indications, syndrome presentations to and elucidating
ARTEMIS-IGAN Our phase internationally. is trial X enrolling
We are sites activate in also advancing to China.
pace that we’ve in investigational of us authorities those the those finalize that recruitment. and and of IgA made submissions and the the clearances and identified Regulatory contract the enrollment Given sites organization trial. expect a size our been the prevalence and accelerate to of nephropathy population large country have China, help working begin we significantly of are research will we and with in number
IgA Society the of the and annual two was inhibitor the ASN, Last role Nephrology the for its the or Journal of examined Professor and MASP-X pathway month Daha, and narsoplimab IgA meeting lectin related of Here published which international at of Mohammed Leiden week of see the American University publication Emeritus specifically of narsoplimab in nephropathy. the again, the subject Netherlands, disease Clinical Medicine. author we senior for Last was in thought presentations. The manuscript support leader narsoplimab. in Dr. is a
patients. and Richard results Dr. detailed Medicine IgA Phase by follow of Nephrology presented up Professor narsoplimab University, Stanford the nearly at first nephropathy on of years of three X Lafayette, The
one, improved rate a stabilized or and period, receiving a proteinuria time on progression Overall risk matched determine predicted assessed narsoplimab or dialysis stage filtration substantially represents adopted XX has course one renal compared the or control for by median than of with term and function by the renal reduction reductions glomerular in of renal narsoplimab then any to delay need the the annually, drug received companies dialysis, in that treated long in group of of other patient’s to unprecedented by of same EGFR by and less. approach of versus estimated the reduction only years disease analytical proteinuria more greater or patients renal to During year for course been as patients standard dialysis a disease. Using substantially per XX% to impact of of proteinuria other seen week need delay X care. longer phase to reported projected reduction treatment XX patients, XX% proteinuria is development a end for This for EGFR.
and Clinical kidney samples the complement by use treatment. as and describing of evaluate narsoplimab collected assess rapidly on a as woman vasculitis. was function narsoplimab Peter the with complement conducted Narsoplimab markers the Garrett during at of substantial from non Chair Further kidney Professor Molecular the effects was urine The deteriorating IgA treatment levels and of report urinary This measured are disease. monitor of study accessible urinary by levels a of in responses Medicine in the the complement Copenhagen. Denmark clinical stabilization reduction summarizes consortium ASN invasive of resource to The readily led Dr. activation at University to UK, pathway with to young with first a course inhibition local the work associated EGFR. studies by and second and presentation by of ongoing lectin
in is program with narsoplimab patients X phase other aHUS. Our
inclusion Quantum Collaborative remains open, than trial, only Our other Healthcare results. trial. the inhibitors COVID-XX the to have leading funded aHUS resources Narsoplimab the by being platform we a University by the in I-SPY are BARDA. Leap part in is and to trial trial a is I-SPY Two COVID-XX COVID-XX programs. forward of as look X evaluated other field publication. for we running the Cambridge. to prioritized our complement seeing part sponsored no in In also and patients. phase for involvement meantime, and continues in nationwide of selected drug is work trial be the laboratories has manuscripts at has severe providing the Omeros although continued Narsoplimab in The trial prepared
assays from University their loss that COVID-XX specific The response exploring therapeutic patients lectin or a acute in very has by of lectin means causes caused from SARS, consumption exceedingly severe first and to are hospitals hospitalized hyper COVID-XX complement and samples shown biobank. complement to of through affiliated profile directed number marker as activity sequelae of Omeros could pathway. Narsoplimab adaptive profile is large evaluation indicator biomarkers impairing and and pathway the antibody activation the team data to activation in sera the we with Bergamo pathway of UK production early pathway associated two major that been by response. This property high. relevant demonstrate of The an the a post that complement lectin lectin pathways, restore the COVID-XX functional patients central pathway hyper classical function. national broad and directed response. a and now classical be inhibition trial of to to between the the in well. a specifically position classical early The pathway the classical COVID-XX show studying prove as components of the and lectin pathway a restore identified plays function longhaul is role this is blood intellectual as disease our disease, activation Cambridge, shared COVID the also assess of in were severe classical of is pathway This this immune developing can of Narsoplimab COV-X abnormalities
very manuscript just COVID-XX. extremely lectin first on the builds as in The severe activation discussed is second pathway high early
secondary between the well the result, complement uncontrolled pathways, pathway its shared of important benefit and and inhibitors its a supports complement severe the infections secondary infections complement life blocks further ability of immunomodulators severe fighting of morbidity mortality lectin suggests restoring anti impaired additional This classical of threatening microbial Narsoplimab clarify the incidence protects likely in occurs critically patients. activity it of immune functional COVID-XX Also, against substantial unlike rather in severe allowing This and COVID-XX. Again, in the ability in manuscripts. other could patients by As and should classical adaptive fight fend publishing COVID-XX. infection to which two the reducing to the the Narsoplimab an clearly is and not dependent why adaptive recovery their but defense explain activation in pathway response forward COVID-XX look the does these component increase supplement risk complement severely We infection opportunistic infection maintaining off immune response. important infections. to prevent consumption that classical in
now of $XX.X million. at revenue Let’s million, third X.X% Net look OMIDRIA quarter in financial prior of up from sales were $XX our revenue from the the third quarter results. quarter’s
quarter Our loss third cash the share, per share $X.XX or was $XX.X per net million $X.X million, were of or non $X.XX which for expenses.
investments. $XX.X million in XX, and equivalents cash, short September of term we had cash As
We we to resolve matter. are as tightly the managing Narsoplimab work BLA our expenditures
neutral approval we Narsoplimab is Given yet Narsoplimab slightly in not positive. or force, field the flow hired have that either cash sales delay
our We programs. costs, development on temporarily focus of complement and primarily our some we as are deferring research
through we $XX of facility. receivable and accounts with on credit addition, million based $XXX aftermarket borrowing an to available up an unused additional million our line have In an availability
quarter, revenues surgery fourth the grow, weekly the time highs sales repeated achieving or continued During ASCs. OMIDRIA have in with centers all to ambulatory
If payment as of well outpatient its Hospital strong Our American associations Academy from Association, American express rule issued Hospital support professional both include reconfirmed and In payment see the public and increasing OMIDRIA and of prospective nation American in the pain Association, payment and non final Essential Eye a system gathering or Society Society, of and payment America’s the for the Thalmic Association, provide the Excellence passed, state continue setting. no separate the Surgery California the cataract to from retinal non a prevent hospital standpoint, specialists, only in American outpatient legislative to last refractive From act It Society OMIDRIA this the separate for hospital opioids renewable bill. Ohio confidence societies. of opioid These was but Society the is Care. chambers surgery, of ASCs hospitals, Hospital see the outpatient payment national in customers of we in durable behind act. for addiction pain in gratifying would separate as ASC the the Ophthalmology, momentum CMS week, continue ASCs years. the for for bill five no the year for representatives, and Hospitals, OMIDRIA also CMS in not co-sponsoring senators, Congress, in period XXXX XX separate has physicians, in the of to ophthalmic Introduced departments OMIDRIA. like for the both XX the spring ASCs, and drugs pain now management
also its truly public health committees Senate, reported, note that support And shown growing in publications leadership and The includes jurisdiction of significantly in from House bipartisan, in on Republicans current the the key been previously both reduce equal is with reviewed Democrats OMIDRIA As both peer in bill we to congress. effectively has list of is the and a roster It’s and co-sponsors opioids. members forward chambers. well the by organizations. and the supported of look important societies medical of to use passage major to long and
addition of and in benefits two imagery Cataract and accepted the In of benefits publications, were supporting recent those already imagery Surgery. recently Refractive use further detailing opioid publication of manuscripts two the for Journal the to OMIDRIA
in significantly the earlier versus that available further while demonstrates an cataract pain ophthalmology. reduced currently published which an of during study at surgery publication, is comparator. scores the This of fentanyl, online Clinical first of interoperative The active concurrently confirms OMIDRIA JCRS results administration use decreasing
OMIDRIA. benefits manuscript second in day any which evolution at use on opioid be OMIDRIA Commercial the limiting of opioids our risks the in pain and management Chief of cataract should online the patients. update surgery. Officer cataract both for supplement surgery commercial and provide that, the an to The use of activities Dac, of Nadia? discusses The manuscript associated on With Nadia our available now I’ll JCRS risks underscores ask
